The Mount Sinai ADRC is excited to announce our participation in a new nationwide study examining the effect of resveratrol in patients with mild to moderate Alzheimer’s disease (AD). What makes this trial unique is that in addition to the traditional paper and pencil tests, the effects of this medication will be evaluated using MRIs (to assess [...]
Over the past 25 years there have been few changes in the diagnosis of Alzheimer disease (AD) even though our knowledge of the disease and its progression has grown. For example, the current criteria have age cutoffs (between 40 and 90 years of age), but we know now that many people living into their 90’s [...]
The first evidence of a link between history of head injury and risk for developing Alzheimer’s disease (AD) was a case report of AD pathology in the brain of a 38 year-old man who had suf- fered a single episode of a head injury 16 years earlier. This finding lead to the idea that head [...]
Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer’s disease.